Markets
Lite Strategy, Inc. (LITS)
LITSNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.01
+0.0523 (+5.46%) today
At the close, Nov 10, 4:00 PM ET. Pre-market $1.01 +5.46%
+5.46% 1D
- Market cap
- $30.18m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6888 to $2.20
- Average volume
- 602.4k
- Previous close
- $0.9577
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.74m | -$29.87m | -$21.61m | -$11.36m |
| Net income | -$3.64m | -$30.80m | -$23.69m | -$13.02m |
News
8 latest- Stocks Settle Lower on Fed Rate Hike FearsBarchart · 8 minutes ago
- Black Rock Coffee Bar: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 8 minutes ago
- Teva Pharma Issues Innovative Medicines Revenue Outlook RTTNews · 13 minutes ago
- UnitedHealth Just Raised Guidance for the Third Time This Year. Where Will the Stock Be in 3 Years?The Motley Fool · 18 minutes ago
- CGI Inc. Q4 26 Earnings Conference Call At 9:00 AM ET RTTNews · 20 minutes ago
- EPR Properties Plans $500 Mln Convertible Senior Notes Offering RTTNews · 20 minutes ago
- Nurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical Development RTTNews · 30 minutes ago
- Am I Buying the Dip in Broadcom Stock?The Motley Fool · 33 minutes ago
The company
Lite Strategy, Inc. (NASDAQ: LITS) is the first U.S. publicly traded company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug candidates to focus on pioneering institutional-grade digital asset treasury strategies, in partnership with leading innovators across blockchain, finance, and technology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- litestrategy.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.